Schmid, B.C.Oehler, M.K.2015-05-192015-05-192014Maturitas, 2014; 77(2):128-1360378-51221873-4111http://hdl.handle.net/2440/91153Abstract not availableen© 2013 Elsevier Ireland Ltd. All rights reserved.Ovarian cancer; Targeted therapy; Anti-angiogenic therapy; PARP inhibitors; Immunotherapy; Intraperitoneal chemotherapyNew perspectives in ovarian cancer treatmentJournal article003001491910.1016/j.maturitas.2013.11.0090003316653000062-s2.0-84893636462110991Oehler, M.K. [0000-0002-2651-5913]